GlobeNewswire Inc.··NaMediWound Eyes Q1 2026 Results as NexoBrid Gains Market Traction
MediWound to report Q1 2026 earnings May 27, updating investors on FDA-approved burn therapy NexoBrid and late-stage wound care candidate EscharEx.
MDWDfinancial resultsconference call